{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038414","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.008643+00:00","generated_at":"2026-06-04T05:23:12.423942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Iterum Therapeutics posts Q4 net loss $12.4M; NDA resubmission planned early Q2 2024","bullets":["Net loss of $12.4M for Q4 2023; full year 2023 net loss $38.4M; non-GAAP net loss $10.7M (Q4) and $43.8M (FY).","Cash, equivalents & short-term investments $23.9M at Dec 31; raised $7.1M post-period via ATM, extending cash runway into 2025.","NDA resubmission for oral sulopenem in uUTIs on track for early Q2 2024; FDA action expected early Q4 2024 under 6-month review.","Engaged financial advisor to explore strategic alternatives including a sale or license of sulopenem rights.","R&D expenses rose to $9.7M (Q4) and $40.0M (FY) driven by the REASSURE trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038414","json":"https://secwatch.observer/filing/0000950170-24-038414.json","markdown":"https://secwatch.observer/filing/0000950170-24-038414.md","text":"https://secwatch.observer/filing/0000950170-24-038414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/0000950170-24-038414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/itrm-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:23:12.423942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5eb0431da2326f38b70a84231a23ff0a0dce2ba","claim":"Iterum Therapeutics plc reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/0000950170-24-038414-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}